In the fight against dengue, the Unified Health System (SUS) will apply the vaccine produced by the Butantan Institute, with a single dose, in three cities: Maranguape (CE) and Nova Lima (MG), starting on January 17th, and in Botucatu (SP), on the 18th.
The idea is to evaluate the results with the immunization of at least 50% of the residents of these municipalities.
THE target audience will be made up of the population aged between 15 and 59 years old.
“For this strategy, part of the first 1.3 million doses produced by the Butantan Institute will be used,” stated the Ministry of Health, in a note.
Magnification
THE The first batch will also be intended for primary care professionalswho work in basic health units (UBS).
According to the ministry, with the increase in dose production, based on the technology transfer partnership between the Butantan Institute and the Chinese company WuXi Vaccines, the strategy will be gradually expanded to the entire country.
THE The idea is to start with the 59-year-old population and move up to the 15-year-old population.depending on the availability of doses.
Currently, SUS offers the vaccine in two doses (produced in Japan) for adolescents aged 10 to 14.
Effectiveness
The Butantan Institute announced, this week, that the vaccine could help reduce the amount of virus in people infected by the pathogenin addition to maintaining effectiveness against the different genotypes of the virus circulating in Brazil. The conclusion came from research made public by the magazine The Lancet Regional Health – Americas.
Low viral loads generally cause less serious conditions. In the survey, researchers analyzed samples from 365 volunteers who had symptomatic dengue between 2016 and 2021 in 14 states in Brazil.
The study compared data from the vaccinated and unvaccinated groups.
According to the research, although some people were infected after vaccination, the viral load in those vaccinated was considerably lower than in non-immunized participants.
This, as the researchers assessed, demonstrated the effectiveness of the vaccine in inducing an immune response and reducing the replication of the virus in cells.
The dengue vaccine developed by the Butantan Institute was approved by Anvisa after analysis of data from five years of follow-up of the 16 thousand volunteers participating in the clinical trial.
In the public aged 12 to 59 years, the age group recommended by the regulatory agency, the vaccine showed 74.7% overall effectiveness and 91.6% effectiveness against severe dengue and warning signs.
